A Phase 2 interventional study of desogestrel/ethinyl estradiol and ethinyl estradiol and desogestrel/ethinyl estradiol in Hemostasis and Oral Contraceptive, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 27 sites in 4 countries. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Thrombosis with a site in Spain — 4 open to participants now, 6 under way, none of them phase 3. Thrombosis · Spain.
Among the 49 studies in Thrombosis with a site in Spain, this one is the 16th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2011, is one of 3 in phase 2, and was the 14th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →4 of the 49 studies in Thrombosis with a site in Spain are open now. Recruiting first, the newest first:
Fundacion Clinic per a la Recerca Biomédica · Sites in Spain
Ages 18+
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 18+
University of Malaga · Sites in Spain
Ages 18+
Hospital San Carlos, Madrid · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 15 · Phase 4 5
First in 2004; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 261 across the 32 interventional studies, 230 across the 17 observational. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Teva Pharmaceutical Industries, Ltd. has 2 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Thrombosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07519304Hospital Arnau de VilanovaEffectiveness of a Needle-free Connector With Anti-reflux Technology in Reducing Complications From Long Peripheral Venous Catheters in Hospitalised Adult Patients: Randomised Clinical Trial | 2026-12-31 |
| NCT07813377Fundacion Clinic per a la Recerca BiomédicaUsefulness of Thromboelastography as a Predictor of Prognosis in Patients Undergoing Surgery for Glial Tumors and of the Risk of Postoperative Thromboembolic Disease (GliTEM) | 2027-05-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Thrombosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the impact of DR-102, a 28-day oral contraceptive compared to a standard 28-day oral contraceptive regimen on hemostatic parameters in healthy women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
21 days of combination active pills (containing 150 mcg desogestrel \[DSG\]/20 mcg ethinyl estradiol \[EE\]), followed by 7 days of 10 mcg EE, taken orally for 6 consecutive 28-day cycles
Drug: desogestrel/ethinyl estradiol and ethinyl estradiol
21 days combination active pills (containing 150 mcg DSG/20 mcg EE), taken orally and followed by 7 days of no treatment for a total of 6 consecutive 28-day cycles
Drug: desogestrel/ethinyl estradiol
Drug pages: Desogestrel · Ethinyl Estradiol
Drug pages: Desogestrel · Ethinyl Estradiol
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels
Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer
Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen
The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity
The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin
Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity
Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII
Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII
Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance
This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance
This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin
Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol
Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH)
Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin
Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
Time frame: Baseline through Month 6
Of the 351 healthy women screened for enrollment, 293 at 26 centers in the European Union (EU) (21 centers) and Israel (5 centers) met entry criteria and were considered to be eligible for this study.
| Milestone | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Started | 150 | 143 |
| Safety population | 145 | 142 |
| Intent-to-treat (itt) population | 140 | 136 |
| Per protocol (pp) population | 125 | 121 |
| Completed | 116 | 114 |
| Not completed | 34 | 29 |
| Withdrew: Adverse event | 10 | 9 |
| Withdrew: Sponsor request | 9 | 7 |
| Withdrew: Withdrawal by subject | 6 | 10 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Noncompliance | 2 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
Normal range for this hemostatic parameter was 41 to 372 pmol/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| pmol/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Prothrombin Fragment 1 + 2 Levels | 45.0 ± 15.24 | 56.8 ± 15.60 |
Normal range for this hemostatic parameter was 0 to 729 mcg/L. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| mcg/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in D-Dimer | 16.4 ± 10.29 | 13.4 ± 10.46 |
The normal range for this hemostatic parameter was 50% to 147%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal 50% to 147% | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Period in Protein S Total Antigen | -11.4 ± 1.09 | -6.6 ± 1.10 |
The normal range for this hemostatic parameter was 70% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Protein C Activity | 16.3 ± 1.90 | 13.0 ± 1.93 |
Normal range for this hemostatic parameter was 75% to 130%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Antithrombin | -1.6 ± 1.17 | -3.2 ± 1.18 |
Normal range for this hemostatic parameter was 70% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor II Activity | 3.3 ± 0.21 | 3.0 ± 0.21 |
Normal range for this hemostatic parameter was 60% to 150%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VII | 17.9 ± 0.81 | 15.1 ± 0.82 |
Normal range for this hemostatic parameter was 50% to 180%. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| percentage of normal | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Factor VIII | 11.1 ± 1.92 | 10.6 ± 1.95 |
This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 2.00 to 3.36. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| ratio | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Activated Partial Thromboplastin Time (APTT)-Based Activated Protein-C (APC) Resistance | -0.3 ± 0.02 | -0.4 ± 0.02 |
This hemostatic parameter is calculated by dividing the clotting time with APC by the clotting time without APC. Normal range for this measure was defined as a ratio of 0.32 to 1.79. Participants were in a fasting state and had refrained from moderate to vigorous exercise prior to phlebotomy on the day of this lab draw. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| ratio | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Endogenous Thrombin Potential (EPT)-Based Activated Protein-C (APC) Resistance | 0.8 ± 0.04 | 0.7 ± 0.04 |
Normal range for this adrenal parameter was 1906.448 to 4520.504 mg/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| mg/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Corticosteroid-Binding Globulin | 4083.3 ± 159.45 | 3721.8 ± 162.95 |
Normal range for this adrenal parameter was 85.6 to 618.2 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| nmol/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Serum Random Total Cortisol | 239.0 ± 15.67 | 230.8 ± 16.03 |
Normal range for this parameter was 0.35 to 5.5 mIU/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| mIU/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Thyroid-Stimulating Hormone (TSH) | 0.2 ± 0.07 | 0.3 ± 0.07 |
Normal range for this parameter was 28 to 146 nmol/L. Change from baseline was analyzed using a repeated measures analysis of covariance with covariate adjustment for baseline, treatment, month, and the treatment by month interaction.
| nmol/L | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| Least Squares Mean Change From Baseline Over the 6-Month Treatment Period in Sex Hormone Binding Globulin | 163.4 ± 7.29 | 149.1 ± 7.46 |
Collected over Adverse events/serious adverse events were collected from the time of signed informed consent until the the Final Telephone Contact (14 days after completing investigational product) or the Early Termination Visit. Treatment period was 6 28-day cycles.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment I: (DR-102) | — | 0/145 (0%) | 84/145 (57.9%) |
| Treatment II | — | 1/142 (0.7%) | 66/142 (46.5%) |
| Event | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| AppendicitisInfections and infestations | 0/145 | 1/142 |
| Event | Treatment I: (DR-102) | Treatment II |
|---|---|---|
| MetrorrhagiaReproductive system and breast disorders | 50/145 | 28/142 |
| HeadacheNervous system disorders | 9/145 | 16/142 |
| Alpha globulin increasedInvestigations | 11/145 | 8/142 |
| Prothrombin level increasedInvestigations | 8/145 | 7/142 |
| DysmenorrhoeaReproductive system and breast disorders | 4/145 | 7/142 |
| Breast painReproductive system and breast disorders | 5/145 | 2/142 |
| GastroenteritisInfections and infestations | 1/145 | 4/142 |
| InfluenzaInfections and infestations | 1/145 | 4/142 |
| NauseaGastrointestinal disorders | 4/145 | 2/142 |
| DizzinessNervous system disorders | 4/145 | 0/142 |
Safety Population (all randomized participants who took 1 or more doses of study drug)
| Age, Continuous(years) | Treatment I: (DR-102) | Treatment II | Total |
|---|---|---|---|
| Mean | 26.4 ± 4.98 | 27.0 ± 5.26 | 26.7 ± 5.12 |
| Sex: Female, Male(Participants) | Treatment I: (DR-102) | Treatment II | Total |
|---|---|---|---|
| Female | 145 | 142 | 287 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Treatment I: (DR-102) | Treatment II | Total |
|---|---|---|---|
| White | 140 | 136 | 276 |
| Black | 1 | 1 | 2 |
| Asian | 0 | 1 | 1 |
| American Indian or Alaskan Native | 0 | 1 | 1 |
| Other | 4 | 3 | 7 |
| Weight(kg) | Treatment I: (DR-102) | Treatment II | Total |
|---|---|---|---|
| Mean | 61.6 ± 10.35 | 60.1 ± 9.36 | 60.9 ± 9.89 |
| Body Mass Index (BMI)(kg/m^2) | Treatment I: (DR-102) | Treatment II | Total |
|---|---|---|---|
| Mean | 22.9 ± 3.62 | 22.4 ± 3.06 | 22.6 ± 3.36 |
Ran from Oct 2011 to primary completion in Sep 2012, 10 months.
Results were first posted in Nov 2013, 1 year 1 month after primary completion.
Of 22 phase 2 interventional studies under Thrombosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Desogestrel · Ethinyl Estradiol
Teva Branded Pharmaceutical Products R&D, Inc. →